Zenflow

Executive Summary

Zenflow is a private medical device company focused on a novel, patient-friendly treatment for benign prostatic hyperplasia (BPH), a condition affecting over half of men over 50. Current therapies, including medications and minimally invasive procedures, often involve unwanted side effects or discomfort. Zenflow's procedure is designed to provide durable relief with a simpler, less invasive approach. Founded in 2014 and based in San Francisco, the company has been clinically evaluating its device as a potential optimal solution for BPH. Though financial details and stage are undisclosed, Zenflow's focus on improving patient experience positions it well in the growing BPH treatment market. Success will depend on clinical evidence and regulatory approval. Zenflow's path to market hinges on generating robust clinical data to support FDA clearance and subsequent commercialization. The company is likely pursuing a 510(k) pathway, given the nature of the device. Key risks include clinical trial outcomes, regulatory hurdles, and competition from established minimally invasive therapies like UroLift and Rezūm. If successful, Zenflow's procedure could capture significant market share by addressing unmet needs for patient comfort and efficacy. The company's early-stage status and lack of public disclosure warrant cautious optimism, but its innovative approach and clear value proposition offer substantial upside potential.

Upcoming Catalysts (preview)

• Q3 2026Pivotal Trial Enrollment Completion75% success
• Q4 2026FDA 510(k) Submission60% success
• Q2 2027Early Commercialization or Partnership Announcement40% success